Skip to main content
. 2011 Mar 1;2010:423781. doi: 10.1155/2010/423781

Figure 2.

Figure 2

Reactivation of tumor-reactive memory T cells of cancer patients (here HNO cancer patients) by the ATV-NDV tumor vaccine of the 2nd generation. (A) Protocol for the ex vivo stimulation of T cells from cancer patients by the NDV-based tumor vaccine of the second generation in an autologous setting. Purified T cells isolated from tumor-draining lymph nodes (LN) of HNSCC patients were tested for their capacity to be restimulated and to produce IFN-γ upon contact with various combination of the ATV-NDV tumor vaccine (generated from the autologous tumor) and bsAbs molecules. For that, they were coincubated for 40 hours with the indicated autologous vaccine formulations (tumor) (n = 4). For specificity control, the unrelated human promonocytic tumor cell line U937 (U937) was modified identically and used to reactivate the patients' T cells. (B) IFN-γ ELISPOT results from A. Mean: mean number from triplicates of 4 patients spot forming T cells per 1 million cells. Each patient's T cells were stimulated with four different formulations of either autologous (a–d) or heterologous (e–h) vaccine. T cells of patients no. 2, no. 3, and no. 4 also did not react to the heterologous vaccine (data not shown) (adapted from [42]).